Korea Research Institute of Chemical Technology

The Green Cross Corporation

Korea Institute of Science and Technology

Woo-Kyu Park

Ae Nim Pae

Jinhwa Lee

Yong Seo Cho

Hyunah Choo

Eun-Jung Park

Jeongmin Kim

Hyun Jung Kim

Suk Hoon Kang

Suk Ho Lee

Hee Jeong Seo

Min Ju Kim

Sang Hee Kim

Sang Eun Chae

Jae Yang Kong

Hun Yeong Koh

Myung Eun Jung

Hee-Yoon Lee

Joo Hwan Cha

Gildon Choi

Heeyeong Cho

Ki-Nam Lee

Daeyoung Jeong

Min Woo Lee

Kwang-Seop Song

Mi-Soon Kim

Younggyu Kong

Young-Sik Jung

Jong Yup Kim

Hee-Jong Lim

Jae-Yang Kong

No-Sang Park

Churl-Min Seong

Ho Kyun Han

Junwon Lee

Suk Youn Kang

Kwang Woo Ahn

Ahmed Asif

Joong-Ho Yoon

The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.

Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders

A novel arylpiperazine-containing imidazole 4-carboxamide derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating a depressive disorder are provided.

Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same

A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.

Arylpiperazine-containing purine derivatives and uses thereof

The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine Dreceptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.

Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same

The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.

The present invention relates to a novel medicinal use of pyrazolopyrimidine compounds having superior effect as serotonin 5-HTreceptor ligand thus being useful for the prevention and treatment of central nervous system (CNS) diseases. Accordingly, the pharmaceutical composition comprising pyrazolopyrimidine compounds and their pharmaceutically acceptable salts as active ingredients are useful for the prevention and treatment of serotonin 5-HT-related central nervous system diseases such as obesity, depression, anxiety and withdrawal symptoms due to drug abuse.

Pyrazolopyrimidine derivatives having biological activity on serotonin receptor 5-HT2c

The present invention relates to 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them. More particularly, it relates to 4-hydroxycinnamamide derivatives showing superior antioxidant activity compared to the known antioxidant compounds, their pharmaceutically acceptable salt, and pharmaceutical compositions containing them. It can be usefully used in treating neurodegerative diseases such as aging, cancer, diabetes, ischemic stroke, Parkin's disease, dementia and Huntinton's disease.

4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them

Growing community of inventors

Cheongju-si, South Korea

Woo-Kyu Park